TY - JOUR
T1 - New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
AU - Spencer-Sandino, Maria
AU - Godoy, Franco
AU - Huidobro, Laura
AU - Alvares, Danilo
AU - Cruz, Francisco
AU - Marco, Claudia
AU - Garrido, Macarena
AU - Cabrera, Daniel
AU - Arab, Juan Pablo
AU - Arrese, Marco
AU - Barrera, Francisco
AU - Ferreccio, Catterina
N1 - Publisher Copyright:
© 2025
PY - 2025/7/1
Y1 - 2025/7/1
N2 - Introduction and Objectives: This study aims to assess the performance of Steatotic Liver Disease (SLD) criteria in identifying liver steatosis compared to the NAFLD and MAFLD definitions in an agricultural population in Chile. Patients and Methods: We performed a cross-sectional analysis on the MAUCO cohort, composed of 9,013 individuals aged 38 to 74. Health conditions, socio-demographics, anthropometrics, hepatic ultrasonography, blood pressure, and biological samples were obtained. Participants were classified as NAFLD, MAFLD, or any of the five SLD categories: Metabolic dysfunction-associated steatosis liver disease (MASLD), Metabolic and Alcohol-Associated Liver Disease (MetALD), Alcohol-Associated Liver Disease (ALD), Specific aetiologies, and Cryptogenic. The Framingham cardiovascular risk score and BARD liver fibrosis score were used to assess clinical relevance. Results: Liver steatosis was present in 4,082 participants (45%); SLD criteria captured an additional 176 individuals not classified under NAFLD and 103 not included under MAFLD definition. The main SLD subgroups were MASLD (95%), MetALD (1.9%) and ALD (1.3%). Individuals classified in the MetALD and ALD subgroups exhibited more severe liver steatosis and a higher cardiovascular risk. Notably, participants categorized under specific etiologies and cryptogenic subgroups were younger and had a higher risk for liver fibrosis. Conclusions: The study reveals that SLD offers a more inclusive classification to identify high-risk individuals in the Chilean population, capturing cases that could be missed by NAFLD or MAFLD definitions by using the same resources.
AB - Introduction and Objectives: This study aims to assess the performance of Steatotic Liver Disease (SLD) criteria in identifying liver steatosis compared to the NAFLD and MAFLD definitions in an agricultural population in Chile. Patients and Methods: We performed a cross-sectional analysis on the MAUCO cohort, composed of 9,013 individuals aged 38 to 74. Health conditions, socio-demographics, anthropometrics, hepatic ultrasonography, blood pressure, and biological samples were obtained. Participants were classified as NAFLD, MAFLD, or any of the five SLD categories: Metabolic dysfunction-associated steatosis liver disease (MASLD), Metabolic and Alcohol-Associated Liver Disease (MetALD), Alcohol-Associated Liver Disease (ALD), Specific aetiologies, and Cryptogenic. The Framingham cardiovascular risk score and BARD liver fibrosis score were used to assess clinical relevance. Results: Liver steatosis was present in 4,082 participants (45%); SLD criteria captured an additional 176 individuals not classified under NAFLD and 103 not included under MAFLD definition. The main SLD subgroups were MASLD (95%), MetALD (1.9%) and ALD (1.3%). Individuals classified in the MetALD and ALD subgroups exhibited more severe liver steatosis and a higher cardiovascular risk. Notably, participants categorized under specific etiologies and cryptogenic subgroups were younger and had a higher risk for liver fibrosis. Conclusions: The study reveals that SLD offers a more inclusive classification to identify high-risk individuals in the Chilean population, capturing cases that could be missed by NAFLD or MAFLD definitions by using the same resources.
KW - Metabolic dysfunction-associated fatty liver disease (MAFLD)
KW - Non-alcoholic fatty liver disease (NAFLD)
KW - Steatotic Liver Disease (SLD)
UR - https://www.scopus.com/pages/publications/105009592187
U2 - 10.1016/j.aohep.2025.101919
DO - 10.1016/j.aohep.2025.101919
M3 - Article
C2 - 40318788
AN - SCOPUS:105009592187
SN - 1665-2681
VL - 30
JO - Annals of Hepatology
JF - Annals of Hepatology
IS - 2
M1 - 101919
ER -